Objective
The aim of this study was to investigate to what extent atypical antipsychotics, conventional antipsychotics and anticholinergics
are prescribed simultaneously in daily clinical practice in Europe.
Method
A pharmaco-epidemiological study was carried out in which hospital pharmacists from 45 hospitals in Belgium, Denmark, France,
Germany, The Netherlands and Scotland participated. Prescription data for 2,725 patients (mainly inpatients) who had been
using an atypical antipsychotic for more than 6 weeks were analysed.
Main outcome measure
The frequencies of simultaneous prescription of atypical antipsychotics with other antipsychotics and/or anticholinergics.
Results
In this sample of patients with an atypical antipsychotic 42.1% was prescribed another antipsychotic (24.1% if low-potent
antipsychotics were not included in the analysis) and 30.1% was prescribed an anticholinergic. In total 47.1% of patients
were prescribed an atypical antipsychotic without any other antipsychotic or anticholinergic.
Conclusion
It is common practice to prescribe a combination of atypical antipsychotics and conventional antipsychotics and/or anticholinergics.
This suggests that monotherapy involving an atypical antipsychotic is not considered to be an adequate treatment for a substantial
number of patients in clinical practice.
Keywords Anticholinergics - Antipsychotic agents - Drug therapy combination - Drug use study - Europe - Pharmaco-epidemiology - Polypharmacy
Springer apologises for the long period that it took to prepare this paper for publication